Back to search results

FAST-GO Study: Physical Function in Gastroesophageal Cancer Treatment

This study, called FAST-GO, is looking at how physical function changes in adults receiving chemotherapy (systemic therapy) for early-stage (Stage I, II, or III) gastroesophageal cancer. This includes cancers of the esophagus, where the esophagus meets the stomach (gastroesophageal junction), or the stomach itself. Researchers want to understand how your physical abilities are affected from the start of treatment until about 6 months later. You could be eligible if you are 18 or older, have a new diagnosis of these early-stage cancers, and are planning to start chemotherapy. This is an observational study, meaning you will receive standard treatment, and researchers will collect information about your physical function. The study is currently recruiting 72 participants.

Study design
This is an observational study, meaning participants receive standard treatment and researchers collect information. It aims to enroll 72 participants.
What's involved
You would provide blood samples, complete surveys, and perform physical function tests. You may also be asked to complete an interview.
Compensation
Not stated in the trial record.
Follow-up
Your physical function will be measured through the end of cancer treatment, an average of 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07517211

A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study

Not Yet Recruiting
Not specifiedAges 18+Observational
Jonsson Comprehensive Cancer Center
~72 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in SPPB
Measured over Through the end of cancer treatment, an average of 6 months

Conditions

Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

Explore related trials

Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Adenocarcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Jingran Ji · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

Jingran Ji
[email protected]
310-825-3181
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\* Adults ≥ 18 years old at the start of study treatment.
New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.
Plan to start systemic therapy for resectable or potentially resectable disease.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion

\* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.
Metastatic disease at the time of diagnosis.
Patients who are unable to provide informed consent.
Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.

What this trial measures

  • Change in SPPBThrough the end of cancer treatment, an average of 6 months

    Will characterize the levels of function at each time point and longitudinal changes in function using descriptive statistics (means, SDs, change scores) in the overall patient sample and by pre-treatment/treatment variables. To assess the associations between pre-treatment/treatment variables and change in function, we will use linear regression models with SPPB change score from baseline to 6 months as the dependent variable and pre-treatment demographic, clinical, and geriatric assessment characteristics as the predictor variables, controlling for the patient's pre-treatment level of function. Potential predictors will be examined individually and in a parsimonious multivariable model. We will also fit linear mixed models for each outcome variable using measurements at all time points and examine differences in change over time by pre-treatment/treatment variables using interaction terms. Time will be treated as a categorical variable, using indicator variables of time.